Algae4IBD Consortium
- Company typePrivate
- Founded2021
- HeadquartersQiryat Gat, Israel
- Headcount—
- GTM typeB2B
- OfferingServices
Algae4IBD Consortium firmographics
Firmographics- Name
- Algae4IBD Consortium
- Legal name
- Algae4IBD Consortium
- Website
- https://algae4ibd.eu
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Ownership category
- akta.pro rank
Algae4IBD Consortium industry classification
Industry- Product category
- Biotechnology Research Services
- NAICS
- Aquaculture (11251)
- SIC
- Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Microbiome Modulating Small Molecules & Antibiotic Alternatives (HLAAAFAG)
- akta.pro secondary industries
- Biological CO₂ Utilization (algae/biotech conversion to fuels, chemicals, proteins) (EUABAIAJ), Probiotics (Strains, Spore-Formers, Synbiotic Components) (AFAJAKAE), Prebiotics & Dietary Fibers (Inulin, FOS/GOS, Resistant Starch, Beta-Glucan, Psyllium) (AFAJAKAF), Seaweed & Algae Aquaculture (incl. microalgae) (AFAEAAAE)
Keywords
Where Algae4IBD Consortium is headquartered
LocationHeadquarters
- HQ city
- Qiryat Gat
- HQ country
- Israel
- HQ region
- Middle East
Offices4 records
Markets served
Algae4IBD Consortium business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- EU Horizon 2020 Research Funding: The Algae4IBD project received funding from the European Union's Horizon 2020 Research and Innovation programme under grant agreement N° 101000501. This is a non-dilutive research grant funding the 4-year project duration.
- Research Partnership Services: The consortium provides research services through collaboration with academic partners, hospitals, and companies for algae cultivation, extraction, food development, and pharmaceutical development across 11 countries.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | One time/ perpetual license | Early Bird Summit Ticket |
| Other | One time/ perpetual license | Late Registration Summit Ticket |
| Other | One time/ perpetual license | Conference Dinner |
| Other | One time/ perpetual license | Excursion to Howth |
| Other | One time/ perpetual license | Exhibition Booth (Standard) |
| Other | One time/ perpetual license | Exhibition Booth (Premium) |
| Other | One time/ perpetual license | Summer School Fee |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels10 records
Algae4IBD Consortium product offering
Product offeringCore offering
The Algae4IBD Consortium is a multi-partner research collaboration that screens algae strains for bioactive compounds with anti-inflammatory, antioxidant, pain-relieving, and prebiotic properties, and develops them into functional food prototypes and pharmaceutical leads for inflammatory bowel disease (IBD). The consortium produces research outputs including the Interactive Bioactive Algae Map covering 187 algae strains, algae-enriched food prototypes, scientific publications, and educational resources.
Product overview
Algae4IBD is a research consortium (not a commercial product company) focused on developing algae-based solutions for inflammatory bowel disease (IBD). The consortium is conducting research to identify bioactive compounds from 187 algae strains and develop them into functional foods (such as algae-enriched pesto, butter, chocolates, and gummy bears) and novel pharmaceuticals. Key outputs include the Interactive Bioactive Algae Map (a research database), recipe booklets, factsheets, and scientific publications. The project has 21 partners across 11 countries and aims to deliver solutions by mid-2026, shortening development time from research to market from 10 to 4 years.
Differentiator
Problem solved
Functional benefit
Brands
- Algae4IBD: EU Horizon 2020 research project studying algae and their metabolites to develop functional foods and medications for IBD treatment
- AIMS-cluster
- Algae4IBD Talks
Products and services
- Interactive Bioactive Algae Map A free interactive web map cataloguing 187 algae strains and their potential health-beneficial properties including anti-inflammatory, antioxidant, pain-relieving, and prebiotic activities, available to researchers, industry stakeholders, and interested users.
- Algae-Enriched Food Prototypes Functional food prototypes incorporating algae extracts, including pesto, butter, vegan brownies, fairy cakes, savory cookies, plant-based spreads, confectionery, gummy bears, and chocolates, developed as research outputs to demonstrate the feasibility of algae-enriched functional foods.
- Algae Recipe Booklet A downloadable recipe booklet featuring algae-based recipes including butter, tapenade, foccacia, pesto, chocolate, cakes, gummy bears, vegan burrata, and vegan cheese, accompanied by background information about algae.
- Algae-Based Therapeutics Research Program A multi-disciplinary research program investigating algae compounds for the prevention and treatment of pain, inflammation, and inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, with the goal of shortening the development timeline from research to market from 10 to 4 years.
Quantifiable outcome
- 55%+ of algae strains showed anti-inflammatory activity in testing
- +5 more outcomes
Companies that use Algae4IBD Consortium
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles3 records
Algae4IBD Consortium technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Algae4IBD Consortium partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered core, minor and major.
- TeagasccoreIrish agricultural and food development authority. Dr. Maria Hayes from Teagasc serves as senior researcher and local organizer of the Algae for Health Summit. Hosted taste testing trials at Teagasc Food Research Center in Dublin and developed algae-enriched food prototypes including pesto, baked goods, spreads, and confectionery.
- WileyminorGlobal publishing company sponsoring best talk and best poster prizes (150 EUR each) at the Algae for Health in Food and Pharma Summit.
- Marine Institute (Ireland)majorFunded the Networking Initiative for the Algae for Health Summit under the Marine Research Programme with support from the Government of Ireland.
- Fáilte IrelandmajorNational Tourism Development Authority of Ireland. Provided financial support for the Algae for Health in Food and Pharma Innovation & Industry Summit.
- MIGAL Galilee Research InstitutecoreThe coordinating institution for the Algae4IBD consortium, led by Dr. Dorit Avni who serves as Project Coordinator. MIGAL brings expertise in inflammation and immune system research. Located in Israel, they initiated the project and assembled experts from 11 countries to pursue the EU Horizon 2020 grant.
- European Science Communication Institute (ESCI)coreESC gGmbH manages the Algae4IBD website and handles all project communication and dissemination activities on behalf of the consortium. Based in Oldenburg, Germany. Dr. Melanie Maria Obermeier serves as Media, Press and Communication contact.
- CCMAR - Centre of Marine SciencescoreCentre of Marine Sciences at the University of Algarve in Portugal. Prof. Luísa Barreira leads algae research working with microalgae for 14 years. Hosted the summer school in July 2024 and contributes expertise in microalgae cultivation and bioactive compound discovery.
- NectoncoreEurope's oldest microalgae producer, located in Portugal. Mariana Carneiro serves as Innovation Manager, optimizing cultivation of microalgae for various applications. Operates industrial-scale production with tubular photo-bioreactors of 19,000+ liters. Contributes to understanding scaling challenges and sustainable production methods.
- InnCoCellsmajorEU Horizon 2020 project within the AIMS-cluster. Scientists are looking for new cosmetic ingredients that can nurture the skin microbiome or heal skin inflammation, prospecting plants and residues from agri-food industry.
- MARBLESmajorEU Horizon 2020 project within the AIMS-cluster. Researchers focus on marine microbiomes from sponges, microalgae, and fish, studying molecules with antifungal or antimicrobial properties for disease protection in aquaculture, agriculture, and human health.
- SECRETedmajorEU Horizon 2020 project within the AIMS-cluster. Scientists aim to develop molecules with tailor-made properties for oncology, cosmetics, pharmaceutics, and agriculture by identifying unexploited compounds in marine and extremophilic microorganisms using experimental machine learning.
- San Raffaele HospitalcoreItalian hospital contributing clinical expertise. Dr. Federica Ungaro introduced patient biopsy-based assays for IBD, providing clinically relevant platforms to accelerate translation of research findings.
- AlgaiacoreFrench algae company. Dr. Benoit Quéguineur serves as Partnership Manager. Developed encapsulation technology for algal extracts and contributed to food prototype development including algae-enriched products.
- Yemoja LtdcoreIsraeli algae production company. Dr. Amikam Bar-Gil contributes expertise in microalgae cultivation and strain optimization. Believes in the big potential of algae industry and anticipates increased investment in startups if the project succeeds.
- AIMS-cluster (Algae4IBD, InnCoCells, MARBLES, SECRETed)majorA collaborative cluster of four EU Horizon 2020 funded projects sharing know-how and tackling common challenges. InnCoCells looks for cosmetic ingredients, MARBLES focuses on marine microbiomes for aquaculture and agriculture, and SECRETed develops molecules for oncology, cosmetics, and pharmaceuticals. The cluster aims to benefit individual project outcomes and increase collective reach.
Scale indicators9 records
Recent moves6 records
Expansion highlights5 records
Algae4IBD Consortium competitors and assessment
Company assessmentBroad incumbents
- Chr. Hansen (now Novonesis): Major probiotics and food cultures producer with established gut-health and microbiome offerings. Comparable end-application focus on gut health and bioactive functional ingredients, though using bacterial cultures rather than algae.
- DSM-Firmenich: Global nutrition and health ingredients giant with functional food, microbiome, and prebiotic offerings (including HMO prebiotics). Comparable in combining microbiome science with ingredient commercialization for IBD-adjacent gut health applications.
- Corbion: Global leader in algae fermentation and functional ingredients (including post-Pioneer Algae acquisition). Comparable industrial algae scale-up and functional ingredient development capabilities relevant to Algae4IBD's产业化 ambitions.
- Acadian Seaplants: Established seaweed-based functional ingredient producer supplying extracts for human nutrition, animal feed, and agriculture. Comparable in extracting bioactives from seaweeds/macroalgae for health applications, though serving a broader end-market than IBD.
Direct peers
- Enterome: Clinical-stage biotech developing microbiome-derived therapeutics for inflammatory bowel disease and other immune-mediated diseases. Directly comparable to Algae4IBD's goal of using bioactives to modulate the gut microbiome in IBD, with both pursuing novel non-steroidal, non-biologic mechanisms.
- Vedanta Biosciences: Clinical-stage microbiome therapeutics company developing defined bacterial consortia (including candidates for IBD). Comparable in targeting gut microbiome modulation in IBD via rationally designed biological interventions rather than algae-derived small molecules.
- Microbiotica: Microbiome drug discovery company using high-resolution microbiome analysis to identify therapeutic candidates for IBD and other immune conditions. Compares to Algae4IBD's screening approach for identifying bioactive compounds that influence inflammation and gut health.
- 4D Pharma (now BiomeBank): Microbiome therapeutics company (formerly 4D Pharma) with a focus on inflammatory bowel disease using live biotherapeutics. Comparable target disease and gut-focused mechanism, though 4D uses bacterial strains rather than algae-derived bioactives.
- Cyanotech: Algae-based nutraceutical and natural product company producing spirulina and astaxanthin for health applications. Compares to Algae4IBD's algae cultivation and bioactive compound discovery, though focused on nutritional rather than IBD-specific positioning.
Emerging players
- BiomX: Clinical-stage microbiome company developing phage-based therapeutics for microbiome-related diseases including IBD. Partially comparable: targets gut microbiome modulation in IBD using a different modality (phage) but converging on the same biology Algae4IBD seeks to modulate.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Algae4IBD Consortium social profiles
Digital presenceAlgae4IBD Consortium financial estimates
Financial estimateRevenue estimate
Valuation estimate
Algae4IBD Consortium leadership team
Management profileNumber of profiles
Profiles2 records
Algae4IBD Consortium funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Algae4IBD Consortium M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Algae4IBD Consortium
What does Algae4IBD Consortium do?
The Algae4IBD Consortium is a multi-partner research collaboration that screens algae strains for bioactive compounds with anti-inflammatory, antioxidant, pain-relieving, and prebiotic properties, and develops them into functional food prototypes and pharmaceutical leads for inflammatory bowel disease (IBD). The consortium produces research outputs including the Interactive Bioactive Algae Map covering 187 algae strains, algae-enriched food prototypes, scientific publications, and educational resources.
Is Algae4IBD Consortium a public or private company?
Algae4IBD Consortium is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was Algae4IBD Consortium founded?
Algae4IBD Consortium was founded in 2021.
Where is Algae4IBD Consortium based?
Algae4IBD Consortium is headquartered in Qiryat Gat, Israel, in the Middle East region.
How does Algae4IBD Consortium make money?
Two revenue lines are on record. EU Horizon 2020 Research Funding is the primary driver. The others are research Partnership Services.
Who are Algae4IBD Consortium's main competitors?
Broad incumbents on record are Chr. Hansen (now Novonesis), DSM-Firmenich, Corbion and Acadian Seaplants. Direct peers are Enterome, Vedanta Biosciences, Microbiotica, 4D Pharma (now BiomeBank) and Cyanotech. BiomX is listed as an emerging player.
Does Algae4IBD Consortium have an API?
No public API is recorded for Algae4IBD Consortium.
What industry is Algae4IBD Consortium in?
Algae4IBD Consortium's product category is Biotechnology Research Services. Its primary akta.pro industry code is HLAAAFAG, Microbiome Modulating Small Molecules & Antibiotic Alternatives, with a secondary code of EUABAIAJ, Biological CO₂ Utilization (algae/biotech conversion to fuels, chemicals, proteins). Its NAICS code is 11251 and its SIC code is 2833.